[NICE Technology Appraisal Guidance] Lenalidomide with rituximab for previously treated follicular lymphoma

NICE | April 2020 | Lenalidomide with rituximab for previously treated follicular lymphoma |Technology appraisal guidance [TA627]

NICE has produced evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults.

Full details form NICE 

Lenalidomide with rituximab for previously treated follicular lymphoma

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s